Introgen Therapeutics, Inc. to Present at BIO CEO & Investor Conference
Introgen Therapeutics zu myNews hinzufügen Was ist das?
Introgen Therapeutics, Inc. (NASDAQ:INGN) announced today that it will
deliver a presentation at the Annual BIO CEO & Investor Conference, the
annual investor conference for the biotechnology industry, being held in
New York. David G. Nance, Introgen’s Chairman
and CEO, is scheduled to present on Wednesday, February 13, 2008, at
11:45 a.m. E.T. Mr. Nance’s presentation will
be webcast live and will be available at http://www.introgen.com About Introgen Therapeutics
Introgen Therapeutics, Inc. is a biopharmaceutical company focused on
the development, manufacturing and commercialization of targeted tumor
suppressors, a new class of therapies for the treatment of cancer.
Introgen’s technology delivers targeted
molecular therapies that increase production of normal cancer-fighting
proteins and cytokines. The Company is developing a proprietary pipeline
of product candidates utilizing molecular biomarkers to identify
patients most likely to benefit from its therapies which target central
cancer-causing mechanisms. ADVEXIN®, its lead
product candidate, targets the p53 tumor suppressor and p53 regulatory
pathway, which is associated with over 50 percent of all tumors. The
Company plans to complete regulatory filings in both the United States
and in Europe in the first half of 2008.
